The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research
Open accessAbstract
More than one third of ovarian cancer patients present with ascites at diagnosis, and almost all have ascites at recurrence. The presence of ascites correlates with the peritoneal spread of ovarian cancer and is associated with poor disease prognosis. Malignant ascites acts as a reservoir of a complex mixture of soluble factors and cellular components which provide a pro-inflammatory and tumor-promoting microenvironment for the tumor cells. Subpopulations of these tumor cells exhibit cancer stem-like phenotypes, possess enhanced resistance to therapies and the capacity for distal metastatic spread and recurrent disease. Thus, ascites-derived malignant cells and the ascites microenvironment represent a major source of morbidity and mortality for ovarian cancer patients. This review focuses on recent advances in our understanding of the molecular, cellular, and functional characteristics of the cellular populations within ascites and discusses their contributions to ovarian cancer metastasis, chemoresistance, and recurrence. We highlight in particular recent translational findings which have used primary ascites-derived tumor cells as a tool to understand the pathogenesis of the disease, yielding new insights and targets for therapeutic manipulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal
Ndiaye, M., Lespez, L., Tribolo, C., Rassé, M., Hadjas, I., Davidoux, S., Huysecom, É., & Douze, K. (2024) · Monash University Research Portal (Monash University) · doi:10.3929/ethz-b-000667478 · Cited by 23,868
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Algebraic decay in hierarchical graphs
Garcia, A., Sonnino, G., Malek-Mansour, M.-A., & Baras, F. (1997) · doi:10.1023/a · Cited by 5,187
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Colman (2022) · doi:10.1073/pnas · Cited by 4,370
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2492 · Cited by 2,279
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
A Perivascular Niche for Brain Tumor Stem Cells
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.020 · Cited by 2,197
Ovarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418
Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293
Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution
Shackleton, M., Quintana, E., Fearon, E. R., & Morrison, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.08.017 · Cited by 1,162
Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T. H., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208249 · Cited by 813
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Bapat, S. A., Mali, A. M., Koppikar, C. B., & Kurrey, N. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3931 · Cited by 760
Cancer stem cells: The challenges ahead
Medema, J. P. (2013) · Nature Cell Biology · doi:10.1038/ncb2717 · Cited by 741
ESMO Symposium on Immuno-Oncology 2015 Officers and Organisation
(2015) · Annals of Oncology · doi:10.1093/annonc/ · Cited by 733
Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells
Esser, S., Lampugnani, M. G., Corada, M., Dejana, E., & Risau, W. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.13.1853 · Cited by 715
Genomic and personalized medicine: foundations and applications
Ginsburg, G. S., & Willard, H. F. (2009) · Translational Research · doi:10.1016/j.trsl.2009.09.005 · Cited by 637
Advances in the formation, use and understanding of multi-cellular spheroids
Achilli, T.-M., Meyer, J., & Morgan, J. R. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707181 · Cited by 572
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
Kipps, E., Tan, D. S. P., & Kaye, S. B. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3432 · Cited by 562
Ovarian Cancer Metastasis: Integrating insights from disparate model organisms
Naora, H., & Montell, D. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1611 · Cited by 538
Mechanisms of transcoelomic metastasis in ovarian cancer
Tan, D. S., Agarwal, R., & Kaye, S. B. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70939-1 · Cited by 520
Alvero, A. B., Chen, R., Fu, H.-H., Montagna, M., Schwartz, P. E., Rutherford, T., Silasi, D.-A., Steffensen, K. D., Waldstrom, M., Visintin, I., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7533 · Cited by 489
Multicellular spheroids in ovarian cancer metastases: Biology and pathology
Shield, K., Ackland, M. L., Ahmed, N., & Rice, G. E. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.11.032 · Cited by 412
Self-citationLeffers, N., Gooden, M. J. M., de Jong, R. A., Hoogeboom, B.-N., ten Hoor, K. A., Hollema, H., Boezen, H. M., van der Zee, A. G. J., Daemen, T., & Nijman, H. W. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0583-5 · Cited by 402
Multicellular resistance: a paradigm for clinical resistance?
Desoize, B. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00086-x · Cited by 400
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM
Runz, S., Keller, S., Rupp, C., Stoeck, A., Issa, Y., Koensgen, D., Mustea, A., Sehouli, J., Kristiansen, G., & Altevogt, P. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.08.064 · Cited by 399
Pattern and prognostic factors in patients with malignant ascites: a retrospective study
Ayantunde, A. A., & Parsons, S. L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl499 · Cited by 385
McLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, L., Cho, K. R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45273 · Cited by 380
Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma
Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P., Mottram, P., Curiel, T., Lange, A., & Zou, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4043 · Cited by 379
Huang, S., Robinson, J. B., DeGuzman, A., Bucana, C. D., & Fidler, I. J. (2000) · PubMed · Cited by 369
Vascular endothelial growth factor expression in early stage ovarian carcinoma
Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., Carson, L. F., & Ramakrishnan, S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970701)80:1<98::aid-cncr13>3.0.co;2-a · Cited by 364
Ascitic fluid analysis in malignancy-related ascites
Runyon, B. A., Hoefs, J. C., & Morgan, T. R. (1988) · Hepatology · doi:10.1002/hep.1840080521 · Cited by 361
Interleukin-6, Secreted by Human Ovarian Carcinoma Cells, Is a Potent Proangiogenic Cytokine
Nilsson, M. B., Langley, R. R., & Fidler, I. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0623 · Cited by 349
Byrne, A. T., Ross, L. H., Holash, J., Nakanishi, M., Hu, L., Hofmann, J., Yancopoulos, G. D., & Jaffe, R. B. (2003) · PubMed · Cited by 310
Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes
Keller, S., König, A.-K., Marmé, F., Runz, S., Wolterink, S., Koensgen, D., Mustea, A., Sehouli, J., & Altevogt, P. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.12.028 · Cited by 300
Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer
Curiel, T. J., Cheng, P., Mottram, P., Alvarez, X., Moons, L., Evdemon-Hogan, M., Wei, S., Zou, L., Kryczek, I., Hoyle, G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1272 · Cited by 297
Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant
Hu, L., McArthur, C., & Jaffe, R. B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605626 · Cited by 296
Reinartz, S., Schumann, T., Finkernagel, F., Wortmann, A., Jansen, J. M., Meissner, W., Krause, M., Schwörer, A., Wagner, U., Müller‐Brüsselbach, S., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28335 · Cited by 271
Norian, L. A., Rodriguez, P. C., O'Mara, L. A., Zabaleta, J., Ochoa, A. C., Cella, M., & Allen, P. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2826 · Cited by 270
Cytokines and Immune Response in the Tumor Microenvironment
Mocellin, S., Wang, E., & Marincola, F. M. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200109000-00002 · Cited by 259
The multicellular tumor spheroid model for high-throughput cancer drug discovery
LaBarbera, D. V., Reid, B. G., & Yoo, B. H. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.708334 · Cited by 255
Hu, Y.-L., Tee, M.-K., Goetzl, E. J., Auersperg, N., Mills, G. B., Ferrara, N., & Jaffe, R. B. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.10.762 · Cited by 246
Latifi, A., Abubaker, K., Castrechini, N., Ward, A. C., Liongue, C., Dobill, F., Kumar, J., Thompson, E. W., Quinn, M. A., Findlay, J. K., et al. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23199 · Cited by 243
Self-citationZhang, Y., Tang, H., Cai, J., Zhang, T., Guo, J., Feng, D., & Wang, Z. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.011 · Cited by 242
Latifi, A., Luwor, R. B., Bilandzic, M., Nazaretian, S., Stenvers, K., Pyman, J., Zhu, H., Thompson, E. W., Quinn, M. A., Findlay, J. K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046858 · Cited by 240
Self-citationAhmed, N., Thompson, E. W., & Quinn, M. A. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21240 · Cited by 237
Self-citationRizvi, I., Gurkan, U. A., Tasoglu, S., Alagic, N., Celli, J. P., Mensah, L. B., Mai, Z., Demirci, U., & Hasan, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216989110 · Cited by 234
Ahmed, N., Abubaker, K., Findlay, J., & Quinn, M. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791190175 · Cited by 234
Self-citationIntraperitoneal cancer dissemination: Mechanisms of the patterns of spread
Carmignani, C. P., Sugarbaker, T. A., Bromley, C. M., & Sugarbaker, P. H. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023791229361 · Cited by 232
Dendritic Cells in Immunity and Tolerance—Do They Display Opposite Functions?
Moser, M. (2003) · Immunity · doi:10.1016/s1074-7613(03)00182-1 · Cited by 229
Abubaker, K., Latifi, A., Luwor, R., Nazaretian, S., Zhu, H., Quinn, M. A., Thompson, E. W., Findlay, J. K., & Ahmed, N. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-24 · Cited by 213
Self-citationWang, Y., Niu, X. L., Qu, Y., Wu, J., Zhu, Y. Q., Sun, W. J., & Li, L. Z. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.019 · Cited by 210
Malignant ascites: past, present, and future
Adam, R. A., & Adam, Y. G. (2004) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2004.01.035 · Cited by 209
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
Gubbels, J. A., Felder, M., Horibata, S., Belisle, J. A., Kapur, A., Holden, H., Petrie, S., Migneault, M., Rancourt, C., Connor, J. P., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-11 · Cited by 209
Giuntoli, R. L., Webb, T. J., Zoso, A., Rogers, O. C., Diaz-Montes, T. P., Bristow, R. E., & Oelke, M. (2009) · PubMed · Cited by 199
Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer
Scambia, G., Testa, U., Benedetti Panici, P., Foti, E., Martucci, R., Gadducci, A., Perillo, A., Facchini, V, Peschle, C., & Mancuso, S. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.71 · Cited by 198
Penson, R. T., Kronish, K., Duan, Z., Feller, A. J., Stark, P., Cook, S. E., Duska, L. R., Fuller, A. F., Goodman, A. K., Nikrui, N., et al. (2000) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.2000.00003.x · Cited by 192
Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells
Fang, X., Yu, S., Bast, R. C., Liu, S., Xu, H.-J., Hu, S.-X., LaPushin, R., Claret, F. X., Aggarwal, B. B., Lu, Y., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306662200 · Cited by 192
Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
Lane, D., Matte, I., Rancourt, C., & Piché, A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-210 · Cited by 190
Profiling of cytokines in human epithelial ovarian cancer ascites.
Matte, I., Lane, D. A., Laplante, C., Rancourt, C., & Piché, A. (2012) · Europe PMC (PubMed Central) · Cited by 188
Hudson, L. G., Zeineldin, R., & Stack, M. S. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9171-5 · Cited by 186
Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity
Keng (2011) · Oncology Reports · doi:10.3892/or.2010.1119 · Cited by 180
Plante, M., Rubin, S. C., Wong, G. Y., Federici, M. G., Finstad, C. L., & Gastl, G. A. (1994) · Cancer · doi:10.1002/1097-0142(19940401)73:7<1882::aid-cncr2820730718>3.0.co;2-r · Cited by 173
Cai, J., Tang, H., Xu, L., Wang, X., Yang, C., Ruan, S., Guo, J., Hu, S., & Wang, Z. (2012) · Carcinogenesis · doi:10.1093/carcin/bgr230 · Cited by 173
The impact of T‐cell immunity on ovarian cancer outcomes
Nelson, B. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00614.x · Cited by 172
Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment
Businaro, L., De Ninno, A., Schiavoni, G., Lucarini, V., Ciasca, G., Gerardino, A., Belardelli, F., Gabriele, L., & Mattei, F. (2013) · Lab Chip · doi:10.1039/c2lc40887b · Cited by 162
Shepherd, T. G., Thériault, B. L., Campbell, E. J., & Nachtigal, M. W. (2006) · Nature Protocols · doi:10.1038/nprot.2006.328 · Cited by 161
Zweifel, M., Jayson, G. C., Reed, N. S., Osborne, R., Hassan, B., Ledermann, J., Shreeves, G., Poupard, L., Lu, S.-P., Balkissoon, J., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq708 · Cited by 159
Cell–cell and cell–matrix dynamics in intraperitoneal cancer metastasis
Sodek, K. L., Murphy, K., Brown, T. J., & Ringuette, M. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9351-2 · Cited by 159
MMP-2 functions as an early response protein in ovarian cancer metastasis
Kenny, H. A., & Lengyel, E. R. (2009) · Cell Cycle · doi:10.4161/cc.8.5.7703 · Cited by 155
Burleson, K. M., Hansen, L. K., & Skubitz, A. P. N. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-004-5768-5 · Cited by 150
Disaggregation and invasion of ovarian carcinoma ascites spheroids
Burleson, K. M., Boente, M. P., Pambuccian, S. E., & Skubitz, A. P. N. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-6 · Cited by 146
Kassim, S. K., El-Salahy, E. M., Fayed, S. T., Helal, S. A., Helal, T., Azzam, E. E.-D., & Khalifa, A. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.01.014 · Cited by 144
Mills, G. B., May, C., Hill, M., Campbell, S., Shaw, P. H., & Marks, A. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114784 · Cited by 141
Epithelial ovarian cancer cells secrete functional Fas ligand.
Abrahams, V. M., Chavez, S. L., Kamsteeg, M., Hanczaruk, B., Schwartz, P. E., Rutherford, T., & Mor, G. (2003) · PubMed · Cited by 139
Shield, K., Riley, C. B., Quinn, M. A., Rice, G. E., Ackland, M. L., & Ahmed, N. (2007) · Journal of Carcinogenesis · doi:10.1186/1477-3163-6-11 · Cited by 139
Self-citationThe role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma.
Feldman, G. B., KNAPP, R. C., Order, S. E., & Hellmän, S. (1972) · PubMed · Cited by 133
Serum Evaluation of Interleukin 6 in Ovarian Cancer Patients
Tempfer, C. M., Zeisler, H., Sliutz, G., Haeusler, G., Hanzal, E., & Kainz, C. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1997.4726 · Cited by 133
Syed, V. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.8.617 · Cited by 130
Ahmed, N., Riley, C. B., Oliva, K., Stutt, E., Rice, G. E., & Quinn, M. A. (2003) · The Journal of Pathology · doi:10.1002/path.1441 · Cited by 121
Self-citationChoi, J., Park, S., Leung, P. C. K., & Choi, K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0297 · Cited by 117
Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer
Ahmed, N., Oliva, K., Barker, G., Hoffmann, P., Reeve, S. B., Smith, A. I., Quinn, M. A., & Rice, G. E. (2005) · PROTEOMICS · doi:10.1002/pmic.200401321 · Cited by 117
Self-citationPeritoneal implants from ovarian tumors: CT findings.
Buy, J., Moss, A., Ghossain, M. A., Sciot, C., Malbec, L., Vadrot, D., Paniel, B., & Decroix, Y. (1988) · Radiology · doi:10.1148/radiology.169.3.3186993 · Cited by 116
Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance
Ahmed, N., Abubaker, K., Findlay, J. K., & Quinn, M. A. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24317 · Cited by 113
Self-citationHuman ovarian cancer stem cells
Bapat, S. A. (2010) · Reproduction · doi:10.1530/rep-09-0389 · Cited by 111
Secretion of vascular endothelial growth factor in ovarian cancer.
Santin, A. D., Hermonat, P. L., Ravaggi, A., et al. (1999) · PubMed · Cited by 108
Vathipadiekal, V., Saxena, D., Mok, S. C., Hauschka, P. V., Ozbun, L. L., & Birrer, M. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029079 · Cited by 107
Obata, N. H., Tamakoshi, K., Shibata, K., Kikkawa, F., & Tomoda, Y. (1997) · PubMed · Cited by 105
Schauer, I. G., Zhang, J., Xing, Z., Guo, X. Q., Mercado‐Uribe, I., Sood, A. K., Huang, P., & Liu, J. (2013) · Neoplasia · doi:10.1593/neo.121228 · Cited by 103
Lane, D. A., Robert, V., Grondin, R., Rancourt, C., & Piché, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22840 · Cited by 97
Kenny, H. A., Dogan, S., Zillhardt, M., Mitra, A. K., Yamada, S. D., Krausz, T. N., & Lengyel, E. R. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-98094-2_16 · Cited by 96
The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Carden, C. P., Stewart, A., Thavasu, P., Kipps, E., Pope, L., Crespo, M., Miranda, S., Attard, G., Garrett, M. D., Clarke, P. A., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0996 · Cited by 96
Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets
Ahmed, N., Abubaker, K., & Findlay, J. K. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.06.002 · Cited by 92
Self-citationCohen, S., Bruchim, I., Graiver, D., Evron, Z., Oron‐Karni, V., Pasmanik‐Chor, M., Eitan, R., Bernheim, J., Levavi, H., Fishman, A., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0946-4 · Cited by 92
Chemotherapeutic drugs and human tumor cells cytokine network
Levina, V. V., Su, Y., Nolen, B. M., Liu, X., Gordin, Y., Lee, M., Lokshin, A. E., & Gorelik, E. (2008) · International Journal of Cancer · doi:10.1002/ijc.23732 · Cited by 92
Ghana’s Encouraging Elections: The Challenges Ahead
Gyimah-Boadi, E. (1997) · Journal of democracy · doi:10.1353/jod.1997.0023 · Cited by 87
Molecular Identification of GD3 as a Suppressor of the Innate Immune Response in Ovarian Cancer
Webb, T. J., Li, X., Giuntoli, R. L., López, P. H. H., Heuser-Loy, C., Schnaar, R. L., Tsuji, M., Kurts, C., Oelke, M., & Schneck, J. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2695 · Cited by 82
Bamias, A., Tsiatas, M. L., Kafantari, E., Liakou, C. G., Rodolakis, A., Voulgaris, Z., Vlachos, G. D., Papageorgiou, T., Tsitsilonis, O., Bamia, C., et al. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.02.029 · Cited by 81
Herr, D., Sallmann, A., Bekes, I., Konrad, R., Holzheu, I., Kreienberg, R., & Wulff, C. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.05.002 · Cited by 79
Activated T lymphocytes migrate toward the cathode of DC electric fields in microfluidic devices
Li, J., Nandagopal, S., Wu, D., Romanuik, S. F., Paul, K., Thomson, D. J., & Lin, F. (2011) · Lab on a Chip · doi:10.1039/c0lc00371a · Cited by 78
Tang, Z., Ow, G. S., Thiery, J. P., Ivshina, A. V., & Kuznetsov, V. A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28371 · Cited by 72
Wintzell, M., Hjerpe, E., Lundqvist, E. Å., & Shoshan, M. C. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-359 · Cited by 71
Immunotherapy opportunities in ovarian cancer
Chu, C., Kim, S. H., June, C. H., & Coukos, G. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.2.243 · Cited by 67
Ahmed, N., Riley, C. B., Oliva, K., Rice, G. E., & Quinn, M. A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602495 · Cited by 63
Self-citationHo, C., Chang, S.-F., Hsiao, C.-C., Chien, T.-Y., & Shih, D. (2012) · Journal of Biomedical Science · doi:10.1186/1423-0127-19-23 · Cited by 62
Féki, A., Berardi, P., Bellingan, G. J., Major, A. L., Krause, K., Petignat, P., Zehra, R., Pervaiz, S., & Irminger‐Finger, I. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.12.003 · Cited by 59
Mukherjee, A., Wu, J., Barbour, S. E., & Fang, X. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.340083 · Cited by 59
Microenvironmental Regulation of Ovarian Cancer Metastasis
Barbolina, M. V., Moss, N. M., Westfall, S. D., Liu, Y., Burkhalter, R. J., Marga, F. S., Forgács, G., Hudson, L. G., & Stack, M. S. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-98094-2_15 · Cited by 58
Lane, D. A., Matte, I., Rancourt, C., & Piché, A. (2010) · Journal of Ovarian Research · doi:10.1186/1757-2215-3-1 · Cited by 57
Microfluidic reveals generation of platelet-strings on tumoractivated endothelium
Kleinerüschkamp, F., Barg, A., Schnaeker, E., Huck, V., Schneider, M. F., Steinhoff, M. S., Goerge, T., & Schneider, S. W. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-03-0163 · Cited by 55
Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer
Michael, D. C. (2010) · Frontiers in bioscience · doi:10.2741/3693 · Cited by 54
Overcoming Challenges of Ovarian Cancer Stem Cells: Novel Therapeutic Approaches
Aguilar-Gallardo, C., Rutledge, E. C., Martínez-Arroyo, A. M., Hidalgo‐Mora, J. J., Domingo, S., & Simón, C. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9344-5 · Cited by 53
In vitro Mesothelial Clearance Assay that Models the Early Steps of Ovarian Cancer Metastasis
Davidowitz, R. A., Iwanicki, M., & Brugge, J. S. (2012) · Journal of Visualized Experiments · doi:10.3791/3888 · Cited by 49
Lane, D. A., Matte, I., Rancourt, C., & Piché, A. (2012) · Journal of Ovarian Research · doi:10.1186/1757-2215-5-34 · Cited by 48
Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions
Gillet, J., Wang, J., Calcagno, A. M., Green, L. J., Varma, S., Elstrand, M. B., Trope, C. G., Ambudkar, S. V., Davidson, B., & Gottesman, M. M. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200240a · Cited by 47
Kryczek, I., Gryboś, M., Karabon, L., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0973 · Cited by 45
Davidson, B. (2001) · Analytical Cellular Pathology · doi:10.1155/2001/418547 · Cited by 38
Niche-Dependent Tumorigenic Capacity of Malignant Ovarian Ascites-Derived Cancer Cell Subpopulations
Katz, E., Skorecki, K. L., & Tzukerman, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1233 · Cited by 36
Tran, E., Nielsen, J. S., Wick, D. A., Ng, A. V., Johnson, L. D. S., Nesslinger, N. J., McMurtrie, E., Webb, J. R., & Nelson, B. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015625 · Cited by 36
Correa, R. J. M., Komar, M., Tong, J., Sivapragasam, M., Rahman, M. M., McFadden, G., DiMattia, G. E., & Shepherd, T. G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.01.048 · Cited by 36
Dissecting “PI3Kness”: The Complexity of Personalized Therapy for Ovarian Cancer
Bast, R. C., & Mills, G. B. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0323 · Cited by 34
Kolomainen, D. F., A’Hern, R., Coxon, F. Y., Fisher, C., King, D. M., Blake, P., Barton, D. P. J., Shepherd, J. H., Kaye, S. B., & Gore, M. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.119 · Cited by 32
Lysophosphatidic Acid Disrupts Junctional Integrity and Epithelial Cohesion in Ovarian Cancer Cells
Liu, Y., Burkhalter, R. J., Symowicz, J., Chaffin, K., Ellerbroek, S. M., & Stack, M. S. (2012) · Journal of Oncology · doi:10.1155/2012/501492 · Cited by 23
Tzuman, Y., Sapoznik, S., Granot, D., Nevo, N., & Neeman, M. (2010) · Neoplasia · doi:10.1593/neo.91272 · Cited by 23
Ovarian Tumor-Induced T Cell Suppression Is Alleviated by Vascular Leukocyte Depletion
Bąk, S., Bak, G., Hart, K. M., & Berwin, B. L. (2009) · Translational Oncology · doi:10.1593/tlo.09190 · Cited by 19
Current status of bevacizumab in advanced ovarian cancer
Rossi, L., Tomao, F., Papa, A., Caruso, D., Panici, P. B., Tomao, F., & Venezia, M. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s46301 · Cited by 18
Jeha, S. S., & Worth, L. L. (2005) · Springer eBooks · doi:10.1007/978-0-387-24472-3_14 · Cited by 10
(2003) · PubMed
Cited by
A single-cell landscape of high-grade serous ovarian cancer
Izar, B., Tirosh, I., Stover, E. H., Wakiro, I., Cuoco, M. S., Alter, I., Rodman, C., Leeson, R., Su, M.-J., Shah, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0926-0 · Cited by 504
Technologies and Standardization in Research on Extracellular Vesicles
Gandham, S., Su, X., Wood, J., Nocera, A. L., Alli, S. C., Milane, L., Zimmerman, A., Amiji, M., & Ivanov, A. R. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2020.05.012 · Cited by 494
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 288
Zhao, Y., Cao, J., Melamed, A., Worley, M., Gockley, A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 259
The Untapped Potential of Ascites in Ovarian Cancer Research and Treatment
Ford, C. E., Werner, B., Hacker, N. F., & Warton, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0875-x · Cited by 261
Metadata
- Authors
- Ahmed, N., & Stenvers, K. L.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 3
- Pages
- 256-256
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2009211019
- Cited by
- 482
- References
- 133
- FWCI
- 22.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.